DBV Technologies Receives IND Clearance From FDA To Begin Clinical Trial In Peanut Allergy

Tuesday, Aug. 31st 2010 6:14 AM

DBV Technologies (DBV), a biotech company specializing in food allergy with innovative products for diagnosis and treatment, announced the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application.

Posted on Tuesday, Aug. 31st 2010 6:14 AM | by Share of Cost | in Share of Cost | No Comments »

Leave a Reply

You must be logged in to post a comment.